Month: January 2021

PRESS RELEASENyxoah announces full-body 1.5T and 3T MRI compatibility for the Genio® system to treat Obstructive Sleep Apnea (OSA)Mont-Saint-Guibert, Belgium – 26th January, 2021 – Nyxoah SA (Euronext: NYXH) (“Nyxoah” or the “Company”), a health-technology company focused on the development and commercialization of innovative solutions and services to treat Obstructive Sleep Apnea (OSA), today announces the Company has received CE Mark Magnetic Resonance Imaging (MRI) conditional labeling for the current Genio® neurostimulation-based OSA therapy to treat Obstructive Sleep Apnea.This revised labeling ensures that patients who receive the Genio® system and those already implanted can now undergo full-body 1.5T and 3T MRI diagnostic scans within approved parameters and access the benefits of Genio® unique bilateral stimulation therapy.Olivier...

COMMUNIQUÉ DE PRESSENyxoah annonce la compatibilité avec les scanners IRM corps entier 1,5T et 3T pour son système Genio® qui permet de traiter le Syndrome d’Apnée Obstructive du Sommeil (SAOS)Mont-Saint-Guibert, Belgique – 26 janvier 2021 – Nyxoah SA (Euronext : NYXH) (« Nyxoah » ou « la Société »), opère dans le secteur des technologies de la santé et se concentre sur le développement et la commercialisation de solutions et de services visant à traiter le Syndrome d’Apnées Obstructives du Sommeil (SAOS). Elle annonce aujourd’hui que son système Genio® pour le traitement du SAOS basé sur la neurostimulation a reçu le marquage CE étendu relatif à l’Imagerie par Résonance Magnétique (IRM).Ce marquage élargi assure aux patients qui reçoivent le système Genio® et à ceux qui ont déjà été implantés qu’ils peuvent passer des IRM corps entier...

Bollène, January 26, 2021 07 :00 am (CET)Press Release2020 2nd Half Revenue2020 RevenueDespite Covid crisis and the fire at its plating line at Egide USA, the Egide Group has succeeded to minimize their impact in 2020, and continues its recovery towards sustainable profitable growth.                         Turnover 2020: €29.96 million (-5.8%)Resilience of activity in European market (+ 15.3% /2019)Egide USA revenue was affected in 2H by production interruption (-28.3% /2019). The revenue lost in 2020 is in the range of €5 million, but no order cancellation was registered which means that it will be delivered in 2021.Santier remains stable (+ 0.7% /2019)Strong growth of Egide SA (+ 11% /2019) OutlookThe overall order backlog at year end confirmed resilience to the crises and showing same level compared to December 2019.New customers...

Bollène, 26 janvier 2021, 07:00 (CET)Communiqué de presseCHIFFRE D’AFFAIRES DU 2ème SEMESTRE 2020CHIFFRE D’AFFAIRES 2020Malgré la crise du Covid-19 et l’incendie de sa ligne de galvanoplastie chez Egide USA, le groupe Egide a réussi à minimiser leurs impacts en 2020, et poursuit son redressement vers une croissance durable et rentable.Chiffre d’affaires 2020: 29,96 millions d’euros (-5,8%/2019)Résilience de l’activité sur la zone Europe : (+ 15,3% / 2019)Les revenus d’Egide USA ont été affectés au second semestre par l’interruption de la production (-28,3% /2019). La perte de chiffre d’affaires en 2020 est de l’ordre de 5 millions d’euros, mais aucune annulation de commande n’a été enregistrée, ce qui signifie qu’elles seront livrées en 2021.Santier reste stable (+ 0,7% / 2019)Forte croissance d’Egide...

Full year net sales from continuing operations¹ up 3% (cc², +3% USD):Pharmaceuticals BU grew 5% (cc) driven by Entresto (+44% cc), Zolgensma (reaching USD 0.9 billion), Cosentyx (+13% cc), Ilaris (+31% cc) and the Xiidra acquisition (+95% cc)Oncology BU grew 3% (cc) driven by Promacta/Revolade (+23% cc), Jakavi (+20% cc), Kisqali (+45% cc), Tafinlar + Mekinist (+16% cc) and Piqray (reaching USD 0.3 billion)Sandoz sales were in line (cc, -1% USD), with Biopharmaceuticals growing 19% (cc)COVID-19 negatively impacted demand, particularly: ophthalmology, dermatology and Sandoz retailCore operating income² grew 13% (cc, +9% USD) and Innovative Medicines and Sandoz core margin improved to 35% and 24% of sales respectively, driven by sales growth, lower spend and productivityContinued transformation of Manufacturing and Business Services contributing...

Der Nettoumsatz der fortzuführenden Geschäftsbereiche¹ stieg im Geschäftsjahr um 3% (kWk², +3% USD):Die Geschäftseinheit Pharmaceuticals wuchs um 5% (kWk), wozu vor allem Entresto (+44% kWk), Zolgensma (USD 0,9 Milliarden), Cosentyx (+13% kWk), Ilaris (+31% kWk) und die Übernahme von Xiidra (+95% kWk) beitrugenDie Geschäftseinheit Oncology legte 3% (kWk) zu, getragen von Promacta/Revolade (+23% kWk), Jakavi (+20% kWk), Kisqali (+45% kWk), Tafinlar + Mekinist (+16% kWk) und Piqray (USD 0,3 Milliarden)Der Umsatz der Division Sandoz blieb auf Vorjahresniveau (kWk, –1% USD), während die Biopharmazeutika 19% (kWk) zulegtenCOVID-19 wirkte sich negativ auf die Nachfrage aus, vor allem in der Ophthalmologie, Dermatologie und im Retailgeschäft von SandozDas operative Kernergebnis² wuchs um 13% (kWk, +9% USD), und die Kerngewinnmargen der Divisionen...

Chiffre d’affaires net des activités poursuivies1en hausse de 3% (tcc2, +3% USD):Pharmaceuticals: cette unité opérationnelle a progressé de 5% (tcc), soutenue par Entresto (+44% tcc), Zolgensma (atteignant USD 0,9 milliard), Cosentyx (+13% tcc), Ilaris (+31% tcc) et par l’acquisition de Xiidra (+95% tcc)Oncology: cette unité opérationnelle a enregistré une hausse de 3% (tcc), stimulée par Promacta/Revolade (+23% tcc), Jakavi (+20% tcc), Kisqali (+45% tcc), Tafinlar + Mekinist (+16% tcc) et Piqray (atteignant USD 0,3 milliard)Sandoz: son chiffre d’affaires s’est aligné sur celui de l’an dernier (tcc, -1% USD), tandis que les produits biopharmaceutiques ont progressé de 19% (tcc)La demande a souffert du Covid-19, en particulier l’ophtalmologie, la dermatologie et les ventes au détail de SandozRésultat opérationnel core² en croissance de...

VANCOUVER, British Columbia, Jan. 26, 2021 (GLOBE NEWSWIRE) — Clean Power Capital Corp. (CSE: MOVE)(FWB: 2K6)(OTC: MOTNF) (“Clean Power” or the “Company” or “MOVE”). Clean Power is pleased to announce that PowerTap Hydrogen Fueling, its investee company, has executed a definitive agreement (the “Definitive Agreement”) with Humboldt Petroleum, Inc., Peninsula Petroleum, LLC, and Colvin Oil I LLC (dba GP Energy) (collectively, “the Andretti Group”) to install PowerTap’s innovative modular hydrogen fueling stations starting in the State of California in 2021.The Andretti Group has over 100 company-owned and operated facilities in the United States with 39 in California. In the industry, there are approximately 111,000 conventional/petrol gas stations in the United States, of which over 11,000 are in California. Under the...

VANCOUVER, British Columbia, Jan. 25, 2021 (GLOBE NEWSWIRE) — Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) (“Pure Extracts” or the “Company”), a plant-based extraction company, is pleased to announce that it has entered into its first substantial biomass purchase agreements in order to scale-up its production of both THC and CBD extracts.The Company has recently agreed to purchase 220 kgs of high potency THC cannabis dried flower from a large, Canadian Licenced Producer and it has also agreed to purchase 1,000 kgs of high potency CBD biomass from a top, Western Canada, cultivator. With biomass prices touching new lows, the Company believes that the timing was right for its first strategic purchases, which will drive revenue growth in Q1 2021.The cannabis will be used to produce full spectrum (FSO) THC...

Small business owners strive to take the business to new heights. They have long term plans to grow the business to new regions, introduce new products and to increase sales and revenue. However, this is easier said than done. You need adequate funds to achieve the goals and it is important to choose a lender who aligns with your needs. Hero FinCorp is a well known name in the industry with a strong presence across the length and breadth of the country. The lender strives to help business owners achieve their goals with HeroFinCorp SME loan. A reliable name in the industry, Hero FinCorp is here to make your professional journey easier. They have helped various individuals achieve their goals. If you own a small business and are in need for funds, you need to identify the amount of funds you need. Consider the purpose of borrowing and then...